Evidence of an interaction between nifedipine and nafcillin in humans
Aims: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P‐450 (CYP). However, there has not been any report to date on its possible interaction with nifedipine, an index substrate of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2003
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/3033/1/Evidence_of_an_interaction_between_nifedipine_and_nafcillin_in_humans.pdf http://eprints.um.edu.my/3033/ https://doi.org/10.1046/j.1365-2125.2003.01789.x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aims: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P‐450 (CYP). However, there has not been any report to date on its possible interaction with nifedipine, an index substrate of the enzyme, CYP3A4.
Methods: Nine healthy normotensive subjects participated in this randomized placebo‐controlled two‐way crossover study examining the effects of 5 days’ pretreatment of nafcillin 500 mg or placebo four times daily on the pharmacokinetics of an oral dose of nifedipine 10 mg. Plasma nifedipine concentrations were measured by gas chromatography–mass spectro.
Results: The area under the plasma nifedipine concentration–time curve (AUC0–α) in nafcillin‐pretreated subjects (80.9 ± 32.9 µg l−1 h−1) was significantly decreased compared with subjects who received only nifedipine (216.4 ± 93.2 µg l−1 h−1) (P < 0.001). Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 ± 42.0 l h−1vs 56.5 ± 32.0 l h−1) (P < 0.002).
Conclusions: The results show that nafcillin pretreatment markedly increased the clearance of nifedipine and suggest that nafcillin is a potent inducer of CYP enzyme. |
|---|